Linezolid (as part of an optimized background regimen for MDR-TB)
Treatment for Hiv Aids Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: 300-600mg daily
Effectiveness
75%
Safety Score
50%
Clinical Trials
50
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
300-600mg daily
Time to Effect
1-2 months for significant clinical improvement
Treatment Duration
Linezolid component 6-12 months, total regimen 9-18 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$6,000
Side Effect Mgmt:$5,000
Total Annual:$26,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$70,000/QALY
QALYs Gained
8
Outcome-Based Costs
Cost per Responder
$34,667
Cost per Remission
$34,667
Comparison vs Older MDR-TB regimens without Linezolid
Cost Difference
$-2,000/year
Less expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Linezolid (as part of an optimized background regimen for MDR-TB) Outcomes
for Hiv Aids Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+75%
Common Side Effects
Peripheral neuropathy
+60%
Myelosuppression (anemia, thrombocytopenia)
+20%
Optic neuropathy
+7%
Nausea/vomiting
+15%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov